Real risk to youth mental health is ‘addictive use,' not screen time alone, study finds
As Americans scramble to respond to rising rates of suicidal behavior among youth, many policymakers have locked in on an alarming metric: the number of hours a day that American children spend glued to a glowing screen.
But a study published Wednesday in the medical journal JAMA, which followed more than 4,000 children across the country, arrived at a surprising conclusion: Longer screen time at age 10 was not associated with higher rates of suicidal behavior four years later.
Instead, the authors found, the children at higher risk for suicidal behaviors were those who told researchers their use of technology had become 'addictive' — that they had trouble putting it down or felt the need to use it more and more. Some children exhibited addictive behavior even if their screen time was relatively low, they said.
The researchers found addictive behavior to be very common among children — especially in their use of mobile phones, where nearly half had high addictive use. By age 14, children with high or increasing addictive behavior were two to three times as likely as other children to have thoughts of suicide or to harm themselves, the study found.
'This is the first study to identify that addictive use is important and is actually the root cause, instead of time,' said Yunyu Xiao, an assistant professor of psychiatry and population health sciences at Weill Cornell Medical College and the study's lead author.
Addictive behavior may be more difficult to control during childhood, before the prefrontal cortex, which acts as a brake on impulsivity, is fully developed.
Xiao said interventions should focus on the child's addictive behavior, which is typically treated with cognitive behavioral psychotherapy, rather than simply limiting access to screens.
'If there are early warnings, then for parents, it's important to seek professional help for children with such addictions,' she said. 'We do not know if just taking away their phone will help. Sometimes it can create some conflict in the family, and that is even worse.'
The focus on addictive behavior has important policy implications, shifting more responsibility onto the technology companies that design devices and social media platforms, said Mitch Prinstein, chief science officer at the American Psychological Association.
Policymakers can address addiction by requiring technology companies to introduce 'age-appropriate design' that limits features adolescents find difficult to resist, he said. The United Kingdom introduced a code of this kind in 2020.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
19 hours ago
- Mint
Gilead's bi-annual HIV prevention jab gets FDA approval: How much does it cost and how it works? All you need to know…
American biopharmaceutical major Gilead Sciences, has recieved approval from the United States' Food and Drug Administration (US FDA), for its bi-annual HIV prevention injection, to be marketed as 'Yeztugo'. Gilead shares briefly jumped 3.5 per cent — its biggest gain nearly a month, and rose 17 per cent year-on-year (YoY), till market close on June 18, Bloomberg reported. The stock outperforming a 2 per cent increase in the S&P 500 index. Lenacapavir, marketed under the brand name Yeztugo, has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents — making it functionally akin to a powerful vaccine, according to an AFP report. Hailed by activists as the world's 'best tool' to fight the HIV virus, especially since no vaccine is yet available, the medicine has to be administered only twice a year and are compatible for a wide range of people, as per the report. 'This is a milestone moment in the decades-long fight against HIV. We now have a way to end the HIV epidemic,' Gilead CEO Daniel O'Day said in an emailed statement to Bloomberg. The injection demonstrated 'powerful ability' to ward off HIV infection in two major international studies last year, the BB report added. AFP reported that results from both trials were published in The New England Journal of Medicine, and the journal Science named lenacapavir its 2024 'Breakthrough of the Year'. As many as 1.3 million people are infected with the HIV virus each year, with the highest rate in Africa. Daily pills do work, but can be forgotten by patients or also lead to stigma as the bottle can reveal people's health status. One international study published in November 2024 showed that the drug prevented all but two HIV cases among 2,180 men and transgender people — a rate 96 per cent lower than the background incidence level in that population. And in June 2025, Gilead said a trial of the shot in 2,000 women and adolescent girls in sub-Saharan Africa prevented an 'unprecedented' 100 per cent of HIV cases. It also outperformed the company's old HIV prevention daily oral pill Truvada in both studies. Yes, there are some side effects. Around 1.2 per cent of the people in the study had reactions at the injection site and stopped taking the medicine, the Bloomberg report said. Other reported side effects include headache, and nausea, according to the AFP report. Gilead said it will price Yeztugo at $28,218 per year (around ₹ 24.50 lakh), compared to the $26,400 list price of its daily HIV prevention pill, Descovy. There was no specific price given for India or other global markets. Lenacapavir's current list price for its previously approved use as a treatment for HIV is $39,000 annually, the AFP report noted. 'We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage,' Gilead spokeswoman Blair Baumwell told AFP via email. The jab will compete with GSK-arm ViiV Healthcare's Apretude prevention shot, which is administered alternate months. This jab costs ₹ 15,200 for a 600mg/3ml vial, according to data on IndiaMart. Notably, Gilead already sells the same drug, lenacapavir, as a treatment for people with multidrug-resistant HIV under the brand Sunlenca — priced at ₹ 23000/box for 300 mg tablets in India, according to IndiaMart. The California-based company is looking at making the drug a 'best-seller' in rich countries, but will also be pushed toward faster roll-out in poorer and middle-income countries that face HIV crisis. And analysts surveyed by Bloomberg expect Yeztugo sales to surpass $4 billion per year by 2031. The report added that Gilead has already filed for approval in a number of countries, including Australia, Brazil, Canada, the European Union, South Africa, and the EU Medicines For All program, which helps speed the review of drugs that will be used in developing countries. In October, Gilead signed agreements with six pharma companies to produce and distribute generic versions of the drug in around 120 low-income and middle-income countries, pending regulatory approval, AFP reported. In a separate deal in December, Gilead announced partnership with the United Nations' Global Fund, the US President's Emergency Plan for AIDS Relief (PEPFAR), and others, to purchase doses for two million people. However, Donald Trump's cuts to the PEPFAR program could now impact this development. (With inputs from Bloomberg, AFP)
Time of India
20 hours ago
- Time of India
'No one has to watch someone they love suffer...': Bill Gates sees hope in the fight against Alzheimer's, and it's deeply personal, 5 years after his father's loss
Bill Gates sees hope in the fight against Alzheimer's: It's deeply personal; 5 years after his father's loss Five years ago, Bill Gates experienced one of the most severe personal losses of his life: seeing his father, William H. Gates Sr., suffer through the heartless advance of Alzheimer's disease. In a stunning new essay on Gates Notes, the Microsoft co-founder vividly remembers, 'Watching my brilliant, loving father go downhill and disappear was a brutal experience.' That experience has since driven his dedication to fighting this ruinous condition, not only through philanthropy, but through sheer technological and scientific push. On the cutting edge of Alzheimer's research today, Bill Gates finds reasons for real hope. Following his visit to Indiana University's School of Medicine in 2024, he was invigorated by what he described as "the latest breakthrough": blood tests that could diagnose Alzheimer's years before signs of the disease show up. Combined with recently approved medications that slightly slow the march of the disease, Gates feels the world is moving closer to a day when no one will have to suffer the agony of losing a loved one. As he states, 'We are closer than ever before to a world where no one has to watch someone they love suffer from this awful disease.' Bill Gates' fight against Alzheimer's is deeply personal Alzheimer's is not only a health or numerical problem for Bill Gates—it's personal. More than 7 million Americans have Alzheimer's today, including almost 1 in 9 individuals aged 65 and older. And although treatment advances have seemed glacial, Gates's path has been a witness to love-driven perseverance. Spurred on by his father's pain and his call to action, Gates has emerged as one of the most vocal voices urging more money, improved tools, and increased urgency in Alzheimer's research. Bill Gates on Alzheimer's: 'This simple blood test could change everything' When Gates visited IU's School of Medicine, he discovered a revolution in the making for Alzheimer's care: blood tests to diagnose Alzheimer's. The tests quantify the amount and ratio of amyloid plaques and tau proteins—Alzheimer's signatures in the brain, years before full-blown symptoms emerge. Early detection : Researchers now recognise that Alzheimer's disease starts as much as 20 years before the development of clinical symptoms. Scalable screening : Rather than expensive PET scans or invasive cerebrospinal fluid analysis, a routine blood draw might become a standard part of checkups. Proactive intervention : Precocious diagnosis by blood tests might lead to treatments that halt intellectual decline before such damage to the brain is permanent. Gates calls these advances a "game-changer"—not only for researchers, but also for families and caregivers who have felt helpless against the advancement of the disease. Two FDA-approved drugs: A modest win with massive implications Encouraging therapy isn't confined to diagnosis. In the past few months, the US Food and Drug Administration has licensed two novel Alzheimer's medications that have been demonstrated to moderately decelerate disease exacerbation. Though not cures, these medications constitute a significant turning point—from symptom treatment to addressing core pathology. Proof of concept : These approvals demonstrate proof of the amyloid hypothesis and lead to further innovation. Strengthened pipeline : Researchers and companies are increasingly likely to invest in comparable treatments, converting optimism into economic as well as health momentum. Gates's enthusiasm is palpable: 'When combined with early diagnostics, I really am excited about the future of treating this disease.' Bill Gates warns: Alzheimer's treatment progress at risk without public funding Despite advances in science, Gates warns of an impending crisis: dwindling public funding. Over the past few months, budgets for the National Institutes of Health and connected research agencies have been trimmed, just when momentum is gaining steam. He argues: This is exactly when investment is most needed. Government grants support large-scale clinical trials and early-stage science that private philanthropy cannot support on its own. Scaling up biotech instruments such as blood tests and treatments necessitates infrastructures which only governments can develop and sustain. 'If we pull back now, all this progress could grind to a halt—and no private initiative can fill that gap,' Gates writes. Bill Gates sees a turning point: 'Alzheimer's no longer feels hopeless' Over the past few years, Alzheimer's seemed like a black hole of despair—until now. Gates spotlights some of the reasons why the tide is turning: Technological convergence : Biomarker analysis enabled by AI, cheap genomic technologies, and wearable tech are improving detection accuracy and affordability. Early diagnosis culture : Screening for Alzheimer's might soon become part of normal healthcare, along with blood pressure and cholesterol tests. Global advocacy : An expanding group of caregivers, scientists, business leaders, and foundations making a difference. Tangible progress : From tests to therapies, the gradual trickle of breakthroughs is turning into a flood, exciting scientists as well as sufferers. Gates's vision: A future free from Alzheimer's tragedy For Bill Gates, fighting Alzheimer's is not about making headlines—it's about saving families the emotional anguish he suffered personally. He dreams of a world where: Early detection technologies detect the disease years before symptoms arise. Targeted treatments halt or slow the disease, maintaining quality of life. Funding and public support fuel a massive research pipeline. In his most passionate sentence, Gates pleads: 'We are on the cusp of turning the tide against dementia.' But he also warns that urgency must be followed by action—more money, more research, more courage in science. Also read | Jeff Bezos' Indian Creek property just got a $105 million neighbour; here's who bought the 'billionaire bunker' land
Indian Express
a day ago
- Indian Express
Real risk to youth mental health is ‘addictive use,' not screen time alone, study finds
As Americans scramble to respond to rising rates of suicidal behavior among youth, many policymakers have locked in on an alarming metric: the number of hours a day that American children spend glued to a glowing screen. But a study published Wednesday in the medical journal JAMA, which followed more than 4,000 children across the country, arrived at a surprising conclusion: Longer screen time at age 10 was not associated with higher rates of suicidal behavior four years later. Instead, the authors found, the children at higher risk for suicidal behaviors were those who told researchers their use of technology had become 'addictive' — that they had trouble putting it down or felt the need to use it more and more. Some children exhibited addictive behavior even if their screen time was relatively low, they said. The researchers found addictive behavior to be very common among children — especially in their use of mobile phones, where nearly half had high addictive use. By age 14, children with high or increasing addictive behavior were two to three times as likely as other children to have thoughts of suicide or to harm themselves, the study found. 'This is the first study to identify that addictive use is important and is actually the root cause, instead of time,' said Yunyu Xiao, an assistant professor of psychiatry and population health sciences at Weill Cornell Medical College and the study's lead author. Addictive behavior may be more difficult to control during childhood, before the prefrontal cortex, which acts as a brake on impulsivity, is fully developed. Xiao said interventions should focus on the child's addictive behavior, which is typically treated with cognitive behavioral psychotherapy, rather than simply limiting access to screens. 'If there are early warnings, then for parents, it's important to seek professional help for children with such addictions,' she said. 'We do not know if just taking away their phone will help. Sometimes it can create some conflict in the family, and that is even worse.' The focus on addictive behavior has important policy implications, shifting more responsibility onto the technology companies that design devices and social media platforms, said Mitch Prinstein, chief science officer at the American Psychological Association. Policymakers can address addiction by requiring technology companies to introduce 'age-appropriate design' that limits features adolescents find difficult to resist, he said. The United Kingdom introduced a code of this kind in 2020.
